Login

$COGT SEC Filings

Filed On Filing
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026

05 Oct 2026 Form 4: Ferrante Karen Jean, Director

Granted 759 Stock Option (Right to Buy)

02 Sep 2026 8-K: Entry into a Material Definitive Agreement

On September 1, 2026, Cogent Biosciences, Inc. (the “Company”) entered into a Commercial Supply Agreement (the “Agreement”) with Hovione FarmaCiencia S.A. (“Hovione”) to manufacture bezuclastinib spray-dried dispersion and bezuclastinib ...

31 Aug 2026 Form 4: Morris Arlene, Director

Received 45,510 shares by exercise or conversion ($245K) · Sold 45,510 shares ($1.69M)

27 Aug 2026 144
13 Aug 2026 SCHEDULE 13G/A
10 Aug 2026 8-K: Other Events

We have examined the Registration Statement on Form S-3 (the “Registration Statement”) of Cogent Biosciences, Inc., a Delaware corporation (the “Company”), filed with the Securities and Exchange Commission (the “Commission”) pursuant to ...

10 Aug 2026 424B5
10 Aug 2026 10-Q
10 Aug 2026 8-K: Results of Operations and Financial Condition

On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June 30

31 Jul 2026 SCHEDULE 13G
27 Jul 2026 SCHEDULE 13G/A
06 Jul 2026 Form 4: Ferrante Karen Jean, Director

Granted 627 Stock Option (Right to Buy)

11 Jun 2026 Form 4: Harwin Peter Evan, Director

Granted 17,901 Stock Option (Right to Buy)

11 Jun 2026 Form 4: Ferrante Karen Jean, Director

Granted 17,901 Stock Option (Right to Buy)

11 Jun 2026 Form 4: Cain Christopher W., Director

Granted 17,901 Stock Option (Right to Buy)

11 Jun 2026 Form 4: Shegog Todd, Director

Granted 17,901 Stock Option (Right to Buy)

11 Jun 2026 Form 4: Morris Arlene, Director

Granted 17,901 Stock Option (Right to Buy)

11 Jun 2026 Form 4: Ros Matthew, Director

Granted 17,901 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support